Overview

Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a preliminary, open-label, clinical trial designed to assess the efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients with coronary artery disease. In addition, the study will assess the effects of vortioxetine on heart rate variability in these patients.
Phase:
Early Phase 1
Details
Lead Sponsor:
Thomas Jefferson University
Collaborator:
Takeda
Treatments:
Vortioxetine